相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Outcomes and prognostic factors in adolescents and young adults with ALL treated with a modified BFM-90 protocol
Akhil Rajendra et al.
BLOOD ADVANCES (2021)
A High-Sensitivity 10-Color Flow Cytometric Minimal Residual Disease Assay in B-Lymphoblastic Leukemia/Lymphoma Can Easily Achieve the Sensitivity of 2-in-106 and Is Superior to Standard Minimal Residual Disease Assay: A Study of 622 PatientsKey terms
Prashant R. Tembhare et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2020)
Cytomegalovirus reactivation after bortezomib treatment for multiple myeloma and light chain amyloidosis
Faye A. Sharpley et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2020)
Infection Prevalence in Adolescents and Adults With Acute Myeloid Leukemia Treated in an Indian Tertiary Care Center
Hasmukh Jain et al.
JCO GLOBAL ONCOLOGY (2020)
A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403
Wendy Stock et al.
BLOOD (2019)
First Analysis of the UKALL14 Phase 3 Randomised Trial to Determine If the Addition of Rituximab to Standard Induction Chemotherapy Improves EFS in Adults with Precursor B-ALL (CRUK/09/006)
David I. Marks et al.
BLOOD (2019)
The combination of bortezomib with chemotherapy to treatrelapsed/refractory acute lymphoblastic leukaemia of childhood
Alice Bertaina et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Munster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen
Michael E. Rytting et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Role of peripheral blood minimum residual disease at day 8 of induction therapy in high-risk pediatric patients with acute lymphocytic leukemia
Thais Ditolvo da Costa Salina et al.
SCIENTIFIC REPORTS (2016)
Therapeutic Drug Monitoring of Posaconazole in Adult Acute Myeloid Leukemia (Aml) Patients Receiving Posaconazole Prophylaxis during Induction: Experience from a Center with High Invasive Fungal Infection (IFI) Burden
Manju Sengar et al.
BLOOD (2016)
Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia Results of cancer and leukemia group B study 19802
Wendy Stock et al.
CANCER (2013)
Has MRD monitoring superseded other prognostic factors in adult ALL?
Monika Brueggemann et al.
BLOOD (2012)
Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study
Yoav H. Messinger et al.
BLOOD (2012)
Chemoimmunotherapy With a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome-Negative Precursor B-Lineage Acute Lymphoblastic Leukemia
Deborah A. Thomas et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Immunochemotherapy with Rituximab Improves Molecular CR Rate and Outcome In CD20+B-Lineage Standard and High Risk Patients; Results of 263 CD20+Patients Studied Prospectively In GMALL Study 07/2003
Dieter Hoelzer et al.
BLOOD (2010)
Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia
Deborah A. Thomas et al.
BLOOD (2009)
Pediatric-Inspired Therapy in Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: The GRAALL-2003 Study
Francoise Huguet et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy
Michael N. Dworzak et al.
BLOOD (2008)
Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo
M. Wang et al.
LEUKEMIA (2008)
Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial
Anthony V. Moorman et al.
BLOOD (2007)
Bortezomib interactions with chemotherapy agents in acute leukemia in vitro
TM Horton et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993
JM Rowe et al.
BLOOD (2005)
Proteasome inhibition as a therapeutic strategy for hematologic malignancies
CS Mitsiades et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2005)
Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults?: Comparison of the French FRALLE-93 and LALA-94 trials
N Boissel et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
分享论文
